Introduction
============

Interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) have been demonstrated to play a significant role as inflammatory mediators in systemic juvenile idiopathic arthritis (SJIA). Tocilizumab, a humanized anti-IL-6 receptor antibody, becomes a new biologic treatment for SJIA nowadays but the correlation of serum IL-6 levels and serum sIL-6R levels with disease activity in SJIA with and without tocilizumab treatment are still unclear.

Objectives
==========

To determine the correlations of serum IL-6 levels and serum sIL-6R levels with disease activity in SJIA patients with and without tocilizumab treatment

Methods
=======

SJIA patients in pediatric rheumatology clinic, Ramathibodi hospital between September 2011 and June 2013 were enrolled in this study. Patients were followed up three times in 2-3 months interval. Fifteen healthy children were included as normal controls. Demographic data was collected. During the visit, patients were evaluated according to Juvenile Arthritis Disease Activity Score-71 (JADAS-71) and blood samplings were collected for complete blood count, erythrocyte sedimentation rate, IL-6 levels, and sIL-6R levels, then patients were categorized into 4 groups; 1) active disease with systemic features and arthritis 2) active disease with only arthritis 3) remission on medication 4) remission off medication

Results
=======

Forty-two SJIA patients, 131 blood samplings were included in this study. Seventeen patients (40%) were treated with tocilizumab during the study. Serum IL-6 levels in patients without tocilizumab treatment significantly elevated in active disease with systemic features and arthritis \[median (IQR) = 101.8 (303.2) pg/mL\] when compared to active disease with only arthritis \[median (IQR) = 4.5 (23) pg/mL\], and remission on medication \[median (IQR) = 1.5 (0.55) pg/mL\], whereas serum IL-6 levels in patients with tocilizumab treatment were not different between groups but there were significantly different when compared to healthy children (p \< 0.05). In addition, the correlation between serum IL-6 levels and JADAS-71 in patients without tocilizumab treatment (r = 0.71, p \< 0.001) was stronger than patients with tocilizumab treatment (r = 0.42, p = 0.01). Serum sIL-6R levels in SJIA patients with and without tocilizumab treatment were significantly higher when compared to healthy children (p \< 0.05). Interestingly, in patients with tocilizumab treatment, serum sIL-6R levels were extremely higher \[median (IQR) = 1,110.3 (840.2) ng/mL\] than patients without tocilizumab treatment \[median (IQR) = 94.2 (82.7) ng/mL\].

Conclusion
==========

The correlation between serum IL-6 levels and disease activity in patients without tocilizumab treatment was stronger than patients with tocilizumab treatment. In addition, serum sIL-6R levels in patients with tocilizumab treatment were extremely higher than patients without tocilizumab treatment.
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